Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07239986Phase 2Not Yet Recruiting

A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

Role: lead

NCT06258408Phase 1Recruiting

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

Role: lead

NCT06143007Phase 1Active Not Recruiting

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors

Role: lead

All 3 trials loaded